Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There have been price expectations and analytical upgrades to as much as $8 a share?
With news of any substance share price could flow past recent resistance near $7?
WE WILL SEE!
GO OCX
"PEACE"
Me too! How big of a bounce you thinking?
Agreed. Should and would be a premier buyout candidate? they ruled out partnering with anyone at this time?
HOLDING, WAITING FOR THE BIG BOUNCE!
GO OCX
"PEACE"
Why is there no updated news on this company? Should be skyrocketing with more news, Let’s go OCX!
Here's Why OncoCyte Is Giving Back Some Gains Today
[Motley Fool]
What happened
Shares of OncoCyte (NYSEMKT: OCX), a company developing noninvasive cancer tests, are giving back some of yesterday's gains. Successful validation of OncoCyte's liquid biopsy sent shares soaring 208% yesterday. The stock has tumbled 15.6% during early-morning trading and was down by 10.5% as of 11:45 a.m. Wednesday.
So what
OncoCyte is a modestly funded operation with explosive sales potential. Its DetermaVu liquid biopsy test for lung cancer recently demonstrated results that suggest it might work. The company used 250 blood samples from patients who had also undergone biopsies, and DetermaVu correctly identified malignancies 90% of the time.
OncoCyte's test also correctly identified benign growths 75% of the time. At the moment, the only way to know if tiny spots that show up on a CT scan are malignant is to reach inside and pull out a chunk of the lung. Around one in five lung cancer biopsies result in potentially serious complications, which makes screening for lung cancer a tough decision for patients and their physicians. DetermaVu isn't meant to replace the use of biopsies, but it could be extremely useful for determining whether performing one is worth the risk.
Now what
The company thinks annual DetermaVu revenue can reach $2.1 billion as a test for patients with large nodules that show up on CT scans, and $4.7 billion if expanded to include medium-size growths as well. The company has another validation study to complete later this year and expects to launch DetermaVu in the second half if all goes according to plan. In recent years, the FDA has threatened to crack down on new lab tests that heavily influence treatment decisions, and the agency could decide DetermaVu needs to jump through a lot more regulatory hoops than expected.
Full-scale clinical trials to please the FDA would cause expenses to explode for OncoCyte, but investors need to brace for a secondary share offering even if all goes according to plan. OncoCyte finished September with just $11.8 million in cash after losing $11.2 million during the first nine months of 2018.
https://finance.yahoo.com/news/apos-why-oncocyte-giving-back-171500642.html
Well this and the fact that some are rightfully exiting with profits.
Volume on yesterday over 44m vs today a little over 6m? A huge upside still exist.
WE WILL SEE...........
GO OCX
"PEACE"
BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
https://finance.yahoo.com/news/biotime-inc-affiliate-company-oncocyte-130000269.html
Looks worth getting a piece of this one also...
GO OCX
"PEACE"
Today's Research Reports on Trending Tickers: Amgen and OncoCyte
https://finance.yahoo.com/news/todays-research-reports-trending-tickers-130000490.html
GO OCX
"PEACE"
Has OncoCyte Changed How We Will Diagnose Cancer in the Near Future?
ACCESSWIRE•January 30, 2019
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on OncoCyte Corporation (NYSE American: OCX) focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer.
On Tuesday, January 29, 2019, the company shares soared significantly on news that a study of their cancer diagnosis test indicated positive results
https://finance.yahoo.com/news/oncocyte-changed-diagnose-cancer-near-133000281.html
GO OCX
"PEACE'
OCX.....Okay i'm in for a sip, taking some advantage of this post rocket-up dip.
Could go lower, as Clay Trader and the gang floor her. But if what they've got is further confirmed as fact, then the share price will again react.
More speculative gains to be made here, both short and long term.
WE WILL SEE........
GO OCX
"PEACE"
* * $OCX Video Chart 01-29-2019 * *
Link to Video - click here to watch the technical chart video
OCX out at 5.89,see yea next time
OCX~~5.85 wowwwwwwwwwwwwwwwwww
OCX~~WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE,200%%% +++ going
* * $OCX Video Chart 07-10-18 * *
Link to Video - click here to watch the technical chart video
They have many warrants flying around, so its a lotto.
gravity has set in compared to AH yesterday
OT: ISR in my opinion yesterday's play as "news"not that big except on technical wig try ons.
that is indeed a massive gap, 164000 shares sold and it went to $4.95.
Cannot wait to see what tomorrow brings.
and then a GINORMOUS gap up in AH
OCX $$$$ HUGE BUYOUT OFFER COULD BE COMING...NO SHARES LEFT $$$$ WOW!!!..
76 percent of the shares are owned by Biotime, and they are not for sale. With an OS of 32 mil shares, that leaves only 7.7 million shares available to trade, as the recent 8 million shares from the placement are restricted for sale. A whiff of volume and this thing will fly.
Huge drop from over 6 Dollar 3 months ago, no doubt the people buying into this placement of shares were responsible for some of that, to push the share price to just under the placement price of $1.26, hence why it rebounded so violently the day after the placement was confirmed.
Still lots of room for this thing to move 50 Day MA is a $3.03 the next one the 200 day MA is all the way up at $4.76.
I reckon it will go through the 50 Day MA very easily on the way to the 200 Day MA.
And it certainly did! up 7% on the day in a blood red market, that is very good going. No doubt many eyes will look at this one tonight, as todays green stocks will stand out like a sore thump.
Once they realised how oversold this thing is and how far it can still go up, there will be a lot of buying decisions made I am sure.
Tomorrow could be huge if DOW makes a rebound.
POWER-HOUR HERE...OCX...IS GOING TO ROCK...
OCX one of only a handful of stocks in the green today, very bullish IMO, if DOW turns tomorrow expect to see increased volume here and an exploding share price.
Very encouraging trading today, holding out for $7
agreed,bids moving up,will break here
OCX $$$ READY TO BLOW UP !!!! READY FOR $10.00++
OCX~~will run hard to $7.00
It could indeed take off, with the money just raised they will have enough to get their lung cancer test kit in the market, this could become quite a revenue earner.
They have no debt and are not in risk of any bankruptcy, with only 40 mil OS including the ones from recent placement and an amazing product line, they could indeed become quite a successful company,
OCX $$$$ COULD BE HUGE NEXT WEEK...$8.00- $10.00 VERY POSSIBLE.
OCX~~HUGE HERE Purpose of Transaction.
The Reporting Persons have acquired their Shares for investment and are filing this Schedule 13D/A to report a change in their beneficial ownership percentage of the Shares, as indicated in Item 5 below.
In connection with the Issuer’s private placement of Shares, on March 28, 2018, the Issuer and Broadwood Partners entered into a Securities Purchase Agreement pursuant to which Broadwood Partners acquired 3,968,254 Shares at a purchase price of $1.26 per share. The foregoing description is not, and does not purport to be, complete and are qualified in their entirety by reference to the full text of the Form of Securities Purchase Agreement, which has been filed as Exhibit B hereto and is incorporated herein by reference.
Except as otherwise set forth herein, the Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present board of directors of the Issuer (the “Board of Directors”) or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be authorized to be quoted in the NASDAQ inter-dealer quotation system; or (g) causing the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934.
The Reporting Persons, however, reserve the right at a later date to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own.
The Reporting Persons have been, and may continue to be, in contact with members of the Issuer’s management, the Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value.
The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer.
Item 5. Interest in Securities of the Issuer.
(a) – (d) As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 8,620,895 Shares, constituting 21.3% of the Shares, based upon 40,461,027 Shares outstanding as of the date hereof as adjusted for warrants beneficially owned by Broadwood Partners. Broadwood Partners has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 8,620,895 Shares. Broadwood Partners has sole power to dispose or direct the disposition of 0 Shares the shared power to dispose or direct the disposition 8,620,895 Shares.
As of the date hereof, Broadwood Capital may be deemed to be the beneficial owner of 8,620,895 Shares, constituting 21.3% of the Shares, based upon 40,461,027 Shares outstanding as of the date hereof as adjusted for warrants beneficially owned by Broadwood Capital. Broadwood Capital has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 8,620,895 Shares. Broadwood Capital has sole power to dispose or direct the disposition of 0 Shares the shared power to dispose or direct the disposition 8,620,895 Shares.
As of the date hereof, Mr. Bradsher may be deemed to be the beneficial owner of 8,624,040 Shares, constituting 21.3% of the Shares, based upon 40,461,027 Shares outstanding as of the date hereof as adjusted for warrants beneficially owned by Mr. Bradsher. Mr. Bradsher has the sole power to vote or direct the vote of 3,145 Shares and the shared power to vote or direct the vote of 8,620,895 Shares. Mr. Bradsher has sole power to dispose or direct the disposition of 3,145 Shares the shared power to dispose or direct the disposition 8,620,895 Shares.
Other than the Shares acquired by the Reporting Persons pursuant to the Securities Purchase Agreement as described in Item 4 above, there have been no transactions in the Shares by the Reporting Persons during the past sixty days.
(e) N/A
OCX~~Source and Amount of Funds or Other Consideration.
The funds for the purchase of the 8,620,895 Shares beneficially owned by Broadwood Partners came from its working capital. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.
The funds for the purchase of the 8,620,895 Shares beneficially owned by Broadwood Capital came from the working capital of Broadwood Partners, which is the direct owner of the Shares. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.
The funds for the purchase of the 8,624,040 Shares beneficially owned by Mr. Bradsher came from his personal funds and the working capital of Broadwood Partners. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.
above 2.00 will be awesome close
OCX $$$$ BIG POWER-HOUR..
OCX~~safety money,will run hard
OCX COULD CLOSE $4.00-$5.00 TODAY....
OCX~~MONSTA UPSIDE<<$10,000,000.00 dollars invested here per news
OCX~~AGREED,L2 is wild and institutions BUYING crazy
OCX $$$ COULD SEE $10+...MASSIVE NEWS TODAY !!!
OCX~~1.50 better buy ,MONDAY HUGE
OCX~~$1.30,monsta news OncoCyte Announces the Closing of a $10 Million Private Placement of Common Stock
Print
Alert
Oncocyte Corp. (AMEX:OCX)
Intraday Stock Chart
Today : Wednesday 28 March 2018
Click Here for more Oncocyte Corp. Charts.
OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has closed a private placement of its common stock with two of its current investors. The purchase agreement for the private placement committed the investors to purchase 7,936,508 shares of common stock for $1.26 per share, for total gross proceeds of $10.0 million before deducting offering expenses. Of this amount, OncoCyte has received $8.0 million in gross proceeds from the sale of 6,349,206 shares of common, and one of the investors irrevocably committed to purchasing an additional 1,587,302 shares for gross proceeds of $2.0 million prior to April 30, 2018. OncoCyte intends to use the net proceeds from the offering for the continued development of its liquid biopsy diagnostic tests for the early detection of cancer, complementary acquisitions, working capital and other general corporate purposes.
Chardan Capital Markets, Inc. acted as sole placement agent for the offering.
The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock to be issued and sold in the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, breast and bladder cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.
Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the subsequent closing of $2.0 million, the use of proceeds from the private placement, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, and maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly as such statements should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contacts:
EVC Group LLC
Matt Haines / Michael Polyviou
917-733-9297 / 732-933-2754
mhaines@evcgroup.com / mpolyviou@evcgroup.com
Financial Media Contact:
GIBSON Communications, LLC
Tom Gibson
201-476-0322
tom@tomgibsoncommunications.com
getting very tired of nothing happening in this stock. no liquid biopsy news at all. I am wondering if it was just all BS.
If any one reads this and you know anything please respond.
thanks, Bob
That drop was BS, over a technical non event.
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
138
|
Created
|
01/04/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |